Phathom Pharmaceuticals Ownership
| PHAT Stock | USD 7.95 0.37 4.45% |
Shares in Circulation | First Issued 2018-03-31 | Previous Quarter 71 M | Current Value 72 M | Avarage Shares Outstanding 36.6 M | Quarterly Volatility 19.2 M |
Phathom Stock Ownership Analysis
About 85.0% of the company shares are owned by institutional investors. The company recorded a loss per share of 5.18. Phathom Pharmaceuticals had not issued any dividends in recent years. Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. Phathom Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Florham Park, New Jersey. Phathom Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 77 people. To find out more about Phathom Pharmaceuticals contact Terrie Curran at 877 742 8466 or learn more at https://www.phathompharma.com.Phathom Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Phathom Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Phathom Pharmaceuticals backward and forwards among themselves. Phathom Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Phathom Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Catalys Pacific Llc | 2025-03-31 | 1.2 M | Propel Bio Management Llc | 2025-03-31 | 1.1 M | Morgan Stanley - Brokerage Accounts | 2025-03-31 | 1.1 M | Gw&k Investment Management, Llc | 2025-03-31 | 1.1 M | Geode Capital Management, Llc | 2025-03-31 | 1 M | State Street Corp | 2025-03-31 | 901.4 K | Avidity Partners Management Lp | 2025-03-31 | 800 K | Woodline Partners Lp | 2025-03-31 | 751.7 K | Ubs Group Ag | 2025-03-31 | 707.6 K | Medicxi Ventures Management (jersey) Ltd | 2025-06-30 | 7.5 M | Jennison Associates Llc | 2025-03-31 | 7 M |
Phathom Pharmaceuticals Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Phathom Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Phathom Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Phathom Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Phathom Pharmaceuticals Outstanding Bonds
Phathom Pharmaceuticals issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Phathom Pharmaceuticals uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Phathom bonds can be classified according to their maturity, which is the date when Phathom Pharmaceuticals has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| US717265AM45 Corp BondUS717265AM45 | View | |
| FCX 7125 01 NOV 27 Corp BondUS717265AJ16 | View | |
| US717265AL61 Corp BondUS717265AL61 | View | |
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| BNP Paribas FRN Corp BondUSF1R15XK367 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View |
Phathom Pharmaceuticals Corporate Filings
F4 | 18th of July 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
F3 | 24th of June 2025 The report used by insiders such as officers, directors, and major shareholders (beneficial owners holding more than 10% of any class of the company's equity securities) to declare their ownership of a company's stock | ViewVerify |
8K | 16th of June 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 9th of June 2025 Other Reports | ViewVerify |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Phathom Stock Analysis
When running Phathom Pharmaceuticals' price analysis, check to measure Phathom Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Phathom Pharmaceuticals is operating at the current time. Most of Phathom Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Phathom Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Phathom Pharmaceuticals' price. Additionally, you may evaluate how the addition of Phathom Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.